title: Prevention of venous thromboembolism.
authors.affiliation: Thromboembolism Program, Sunnybrook & Women's College Health Sciences Centre, Toronto, ON, Canada.
authors.forename: W H
authors.initials: WH
authors.lastname: Geerts
authors.forename: J A
authors.initials: JA
authors.lastname: Heit
authors.forename: G P
authors.initials: GP
authors.lastname: Clagett
authors.forename: G F
authors.initials: GF
authors.lastname: Pineo
authors.forename: C W
authors.initials: CW
authors.lastname: Colwell
authors.forename: F A
authors.initials: FA
authors.lastname: Anderson
authors.forename: H B
authors.initials: HB
authors.lastname: Wheeler
mesh_terms: D002056:Burns / Q000150:complications; D003422:Critical Care; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D009369:Neoplasms / Q000150:complications; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control; D011655:Pulmonary Embolism / Q000517:prevention & control*; D018570:Risk Assessment; D013119:Spinal Cord Injuries / Q000150:complications; D020521:Stroke / Q000188:drug therapy; D020246:Venous Thrombosis / Q000453:epidemiology / Q000517:prevention & control*; D014947:Wounds and Injuries / Q000150:complications
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin